Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Cigarette Smoking and Prostate Cancer Mortality in Four US States, 1999-2010.

Jones MR, Joshu CE, Kanarek N, Navas-Acien A, Richardson KA, Platz EA.

Prev Chronic Dis. 2016 Apr 14;13:E51. doi: 10.5888/pcd13.150454.

2.

Melanoma mortality following skin cancer screening in Germany.

Boniol M, Autier P, Gandini S.

BMJ Open. 2015 Sep 15;5(9):e008158. doi: 10.1136/bmjopen-2015-008158.

3.

Principles of Cancer Screening.

Pinsky PF.

Surg Clin North Am. 2015 Oct;95(5):953-66. doi: 10.1016/j.suc.2015.05.009. Review.

4.

Novel prostate cancer biomarkers derived from autoantibody signatures.

Schipper M, Wang G, Giles N, Ohrnberger J.

Transl Oncol. 2015 Apr;8(2):106-11. doi: 10.1016/j.tranon.2015.02.003.

5.

Developing a follow-up strategy for patients with PSA ranging from 4 to 10 ng/ml via a new model to reduce unnecessary prostate biopsies.

Zhao R, Huang Y, Cheng G, Liu J, Shao P, Qin C, Hua L, Yin C.

PLoS One. 2014 Sep 30;9(9):e106933. doi: 10.1371/journal.pone.0106933.

6.

Methods and rationale used in a matched cohort study of the incidence of new primary cancers following prostate cancer.

Cronin-Fenton DP, Antonsen S, Cetin K, Acquavella J, Daniels A, Lash TL.

Clin Epidemiol. 2013 Oct 31;5:429-37. doi: 10.2147/CLEP.S49713.

7.

Prostate cancer screening: Attitudes and practices of family physicians in Ontario.

Allard CB, Dason S, Lusis J, Kapoor A.

Can Urol Assoc J. 2012 Jun;6(3):188-93. doi: 10.5489/cuaj.11290.

8.

The burden of prostate cancer in Asian nations.

Cullen J, Elsamanoudi S, Brassell SA, Chen Y, Colombo M, Srivastava A, McLeod DG.

J Carcinog. 2012;11:7. doi: 10.4103/1477-3163.94025.

9.

An examination of the dynamic changes in prostate-specific antigen occurring in a population-based cohort of men over time.

Inman BA, Zhang J, Shah ND, Denton BT.

BJU Int. 2012 Aug;110(3):375-81. doi: 10.1111/j.1464-410X.2011.10925.x.

10.

What if I don't treat my PSA-detected prostate cancer? Answers from three natural history models.

Gulati R, Wever EM, Tsodikov A, Penson DF, Inoue LY, Katcher J, Lee SY, Heijnsdijk EA, Draisma G, de Koning HJ, Etzioni R.

Cancer Epidemiol Biomarkers Prev. 2011 May;20(5):740-50. doi: 10.1158/1055-9965.EPI-10-0718.

11.

Novel diagnostic biomarkers for prostate cancer.

Madu CO, Lu Y.

J Cancer. 2010 Oct 6;1:150-77.

12.

Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening.

Savage CJ, Lilja H, Cronin AM, Ulmert D, Vickers AJ.

Cancer Epidemiol Biomarkers Prev. 2010 May;19(5):1201-7. doi: 10.1158/1055-9965.EPI-09-1251.

13.

Bayesian Calibration of Microsimulation Models.

Rutter CM, Miglioretti DL, Savarino JE.

J Am Stat Assoc. 2009 Dec 1;104(488):1338-1350.

14.

Generational risks for cancers not related to tobacco, screening, or treatment in the United States.

Han YY, Davis DL, Weissfeld JL, Dinse GE.

Cancer. 2010 Feb 15;116(4):940-8. doi: 10.1002/cncr.24747.

15.

Calibration methods used in cancer simulation models and suggested reporting guidelines.

Stout NK, Knudsen AB, Kong CY, McMahon PM, Gazelle GS.

Pharmacoeconomics. 2009;27(7):533-45. doi: 10.2165/11314830-000000000-00000. Review.

16.

Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.

Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, de Koning H.

J Natl Cancer Inst. 2009 Mar 18;101(6):374-83. doi: 10.1093/jnci/djp001.

17.

Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study.

Collin SM, Martin RM, Metcalfe C, Gunnell D, Albertsen PC, Neal D, Hamdy F, Stephens P, Lane JA, Moore R, Donovan J.

Lancet Oncol. 2008 May;9(5):445-52. doi: 10.1016/S1470-2045(08)70104-9.

18.

Secular trends in prostate cancer mortality, incidence and treatment: England and Wales, 1975-2004.

Hussain S, Gunnell D, Donovan J, McPhail S, Hamdy F, Neal D, Albertsen P, Verne J, Stephens P, Trotter C, Martin RM.

BJU Int. 2008 Mar;101(5):547-55. doi: 10.1111/j.1464-410X.2007.07338.x.

19.

Assessing the impact of prescribed medicines on health outcomes.

Hall WD, Lucke J.

Aust New Zealand Health Policy. 2007 Feb 15;4:1.

20.

Risk factors for prostate cancer.

Gann PH.

Rev Urol. 2002;4 Suppl 5:S3-S10.

Items per page

Supplemental Content

Support Center